Curative Regenerative Drugs Need NICE Rethink, Key U.K. Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Health systems and health technology assessment bodies are unprepared for potentially curative gene and cell therapies, leaving drug makers and researchers in the dark, says influential U.K. parliamentary group.